Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

3 Pharma Powerhouses for Long-Term Growth in 2024

Amid evolving technologies and strategic maneuvers, the pharma industry is set for paradigm-shifting growth, propelled by growing funding and drug discovery. Hence, fundamentally strong pharma stocks Collegium Pharmaceutical (COLL), AstraZeneca (AZN), and Merck & Co. (MRK) might be ideal buys this year for long-term growth. Read more….

StockNews.com

Feds Make a Pharma Patent Grab

A Biden administration ploy could give the federal government control over drug prices.

Reason

As a low-maintenance beauty editor with frazzled hair, I can’t believe the results of this underrated Olaplex product

This is one smooth operator

Marie Claire

From analysis to the latest developments in health,
read the most diverse news in one place.

Drugs shortage sees France restart local production, target antibiotics use

The French government has published a roadmap to address a growing shortage of medicines. It provides doctors and pharmacists with tools to prescribe alternatives, urges the use of fewer antibiotics and jumpstarts local production of key drugs.

Radio France Internationale

New York man pleads guilty to running ‘Breaking Bad-style’ meth lab

‘Brilliant’ scientist Matthew Leshinsky turned himself in after calling the police to report a burglary at his lab in Suffolk county

The Guardian - US

AstraZeneca boss’s £17m pay package under fire

Corporate governance thinktank questions whether Pascal Soriot’s remuneration – 1,000 times the minimum wage – is justifiable

The Guardian - UK

Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Pfizer (PFE) vs. Johnson & Johnson (JNJ) - Analyzing Pharma Stocks for Upside Potential

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

StockNews.com

Brave new world: On the India-European Free Trade Association agreement and IPR

India must invest substantially more in fundamental research to incubate the local drug industry into the future

The Hindu

Dominate the Market With 3 Biotech Stocks

The biotech industry’s growth prospects look promising due to considerable investments in research and development (R&D), an innovative drugs pipeline, government initiatives, the growing popularity of personalized medicine, drug approvals, expanding healthcare needs, etc. Amid this backdrop, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), Foghorn Therapeutics (FHTX),…

StockNews.com

Sempre Health's innovative approach improves medication adherence and lowers costs

Initiatives like GoodRx and Sempre Health are working towards transparency and affordability in the drug supply chain to improve medication adherence. Blue...

Top News

Bolster Your Portfolio with These 3 Pharma Stock Buys

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

StockNews.com

3 Biotech Stocks Making Major Moves on Wall Street

The biotechnology industry is experiencing significant growth, fueled by government initiatives, rising investments and tech advancements. Therefore, it could be wise to consider fundamentally strong biotech stocks Shionogi & Co (SGIOY), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), which are making major moves on wall street. Read more.

StockNews.com

3 Pharma Stocks to Buy for February Gains

The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs, a rapidly aging population, and the rise in chronic diseases. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Bausch Health Companies (BHC), and ACADIA…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

This Week's Biotech Stock Star Performers

The biotech industry is poised for robust growth thanks to the increasing demand for personalized treatments, the rise in chronic diseases, a rapidly aging population, the adoption of advanced technologies, and government initiatives. Therefore, to capitalize on the industry’s growth prospects, one could consider buying fundamentally strong biotech stocks Genmab…

StockNews.com

Unleash Gain Potential With 3 Pharma Stocks to Consider

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

StockNews.com

Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

AAP

Heavy losses for CSL help drag ASX into the red

The Australian share market has finished down 0.4 per cent in large part because of a failed heart attack drug that CSL spent nearly $1 billion developing.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Why Investors Are Flocking to These 2 Medical Stocks

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

Top News

Senate hearings expose pharmaceutical companies amidst rising drug prices

This article discusses a contentious hearing on Capitol Hill where pharmaceutical companies faced scrutiny over high drug prices and their impact on health...

The Guardian - UK

The Guardian view on India-UK trade talks: don’t make it harder for the health service

Editorial: Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma

StockNews.com

3 Growth Pharma Stocks to Guard Your Portfolio

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

StockNews.com

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

StockNews.com

AMGN Earnings Spotlight: Analyzing Potential Gains

Drug manufacturer Amgen Inc. (AMGN) is actively pursuing strategic collaborations and making noteworthy strides in the realm of obesity treatments. With the company all set to lift the curtains on its fiscal fourth-quarter earnings tomorrow, would it be prudent to take a bullish stance on the stock now? Keep reading…

StockNews.com

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

1 … 37 38 39 40

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.